A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 671
- Population
- ALL · 50 Years
- Duration
- 2013-06-03 to 2015-07-09
- Intervention
- Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — up to Month 12; Change From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 12 — up to Month 12; Gain of Equal or More Than 1, 5, 10, or 15 Letters in Visual Acuity of the Study Eye From Baseline, at Month 12 and 24…; Loss of Less Than 5, 10, and 15 Letters in Visual Acuity in the Study Eye From Baseline, at Month 12 and 24 — Baseline…; Visual Acuity of 73 Letters or More in the Study Eye at Month 12 and 24 — Month 12 and 24; Average Visual Acuity Change From Month 3 to Month 4 Through Month 24 in the Study Eye — Month 3 to Month 24; Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and 24 in the Study Eye — Baseline to Month 12 a…; Change From Baseline in Central Sub-Field Thickness (CSFT) and Central Sub-Field Volume (CSFV) of the Study Eye Over Ti…; Dry Retina in the Study Eye on OCT at Month 12 and 24 — Month 12 and 24; Change From Baseline in Lesion Size and Morphology Based on Fluorescein Angiography at Month 12 and 24 — Baseline to Mo…; Treatment Patterns Over Time in Both Treatment Arms — Baseline to Month 12 and 24; Change From Baseline in the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) Scores Over Time — Bas…; Frequency and Severity of Ocular and Non-ocular Adverse Events Over Time — Screening to Month 12 and 24
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.